The impact of controlled release capsules of monensin on postcalving haptoglobin concentrations in dairy cattle.
This study was designed to assess the impact of a controlled release capsule (CRC) of monensin, administered prior to calving, on postcalving haptoglobin levels. The role of disease on haptoglobin levels was also studied. The study population consisted of 1010 cows from 25 Holstein dairy herds near Guelph, Ontario. Monensin CRC or placebo capsules were randomly assigned within each herd 3 wk prior to the expected calving date. Serum from week 1 and week 6 postcalving was submitted for quantification of haptoglobin concentrations. Haptoglobin results were analyzed for associations with treatment, health data, and individual cow factors up to 95 d in milk. Haptoglobin concentrations were higher in week 1 than week 6 (P < 0.05). In univariate analysis, several diseases were significantly associated with haptoglobin concentrations. However, occurrence of disease appeared to be a confounding factor in the data interpretation. Thus, the analysis was stratified by the presence or absence of disease. There appeared to be associations between factors other than clinical disease contributing to increased haptoglobin levels in both clinically healthy and unhealthy cattle. Haptoglobin served as a good indicator of inflammatory disease. Monensin CRC treatment was associated with increased haptoglobin concentrations in clinically unhealthy cattle, perhaps reflecting a better ability to respond to disease challenge. The lower haptoglobin concentrations in monensin CRC treated cattle that were clinically normal may be a reflection of reduced subclinical disease.
Crawford
Rex G
RG
Department of Population Medicine, University of Guelph, Guelph, Ontario.
Leslie
Ken E
KE
Bagg
Randal
R
Dick
C Paul
CP
Duffield
Todd F
TF
D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000097:blood* / Q000276:immunology; D003692:Delayed-Action Preparations; D005260:Female; D006242:Haptoglobins / Q000187:drug effects*; D007476:Ionophores / Q000008:administration & dosage / Q000494:pharmacology*; D007662:Ketosis / Q000097:blood / Q000276:immunology / Q000662:veterinary*; D008985:Monensin / Q000008:administration & dosage / Q000494:pharmacology*; D010298:Parity; D010919:Placebos; D049590:Postpartum Period / Q000097:blood*; D011247:Pregnancy
D003692:Delayed-Action Preparations; D006242:Haptoglobins; D007476:Ionophores; D010919:Placebos; D008985:Monensin